Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Vorinostat

Vorinostat

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Vorinostat

83 trials tracked of Vorinostat: 5 in phase 3 or 4.

83Trials tracked
5Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 5 Phase 2 54 Phase 1 20 Other / NA 4
  1. Phase 3 Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) Completed
  2. Phase 3 Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Completed
  3. Phase 3 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Completed
  4. Phase 3 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed
  5. Phase 3 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) Completed
  6. Phase 2 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma Completed
Show 44 more trials
  1. Phase 2 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed
  2. Phase 2 Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Completed
  3. Phase 2 Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant Completed
  4. Phase 2 Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) Completed
  5. Phase 2 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Completed
  6. Phase 2 Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed
  7. Phase 2 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Completed
  8. Phase 2 The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART Completed
  9. Phase 2 Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant Completed
  10. Phase 2 A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007) Completed
  11. Phase 2 Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma Completed
  12. Phase 2 Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) Completed
  13. Phase 2 Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes Completed
  14. Phase 2 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Completed
  15. Phase 2 Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Completed
  16. Phase 2 Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Completed
  17. Phase 2 Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Completed
  18. Phase 2 Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Completed
  19. Phase 2 Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment Completed
  20. Phase 2 Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) Completed
  21. Phase 2 Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme Completed
  22. Phase 2 Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer Completed
  23. Phase 2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Completed
  24. Phase 2 Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Completed
  25. Phase 2 Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer Completed
  26. Phase 2 Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant Completed
  27. Phase 2 Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Completed
  28. Phase 2 Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed
  29. Phase 2 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Completed
  30. Phase 2 Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer Completed
  31. Phase 2 Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer Completed
  32. Phase 2 Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Completed
  33. Phase 2 Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Completed
  34. Phase 2 Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer Completed
  35. Phase 2 Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer Completed
  36. Phase 2 Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed
  37. Phase 2 Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma Completed
  38. Phase 2 Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma Completed
  39. Phase 2 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed
  40. Phase 2 Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma Completed
  41. Phase 2 Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Completed
  42. Phase 2 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed
  43. Phase 2 Research In Viral Eradication of HIV Reservoirs Completed
  44. Phase 2 Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors Completed

Showing the 50 most-cited and recently-updated of 83 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.